FDA Brief

Warning letters Drugs

FDA warning letter to

Dynamic Blending Specialists, Inc.

High riskIssued Jun 18, 2025Posted Jul 8, 2025Center for Drug Evaluation and Research (CDER)

FDA cited Dynamic Blending Specialists for manufacturing failures in OTC drugs and an unapproved, misbranded oral antiseptic.

What happened

FDA inspected the facility from December 3 to 6, 2024, and reviewed the company’s December 24, 2024 response to the Form FDA 483 (inspection observations). The inspection found significant violations of current good manufacturing practice (CGMP) for finished drugs, including missing identity testing for glycerin and active ingredients, inadequate sampling and water monitoring, and quality-unit and documentation failures. FDA also found a redacted oral antiseptic product was an unapproved new drug and misbranded.

What FDA found

  1. The firm did not perform at least one identity test for each component lot, including glycerin and active ingredients, and relied on suppliers’ certificates of analysis without establishing their reliability.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  2. The firm’s sampling and testing plans for SmileSense Fluoride Toothpaste and KT Tape Pain Relief Gel were not justified as representative of the whole batch, and water system monitoring was not documented.

    21 CFR 211.160(b)
  3. The quality unit did not adequately oversee manufacturing and documentation, including calibration logs, non-conformance records, shred bins containing what appeared to be CGMP records, water records on a personal computer, and support for labeled expiration dates.

    21 CFR 211.22
  4. A redacted oral antiseptic product was an unapproved new drug because its ingredients and claims did not conform to the applicable OTC oral antiseptic proposed rule.

    FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)
  5. The same redacted oral antiseptic product was misbranded because it did not meet requirements for marketing without an approved application.

    FD&C Act section 502(ee), 21 U.S.C. 352(ee)

What FDA wants

FDA tells the company to correct the violations promptly and respond in writing within 15 working days with corrective actions, including a DEG/EG risk assessment and component testing results no later than 30 calendar days from the letter.

Who should pay attention

  • brands that buy OTC drug products from this contract manufacturer
  • companies sourcing toothpaste or topical gels from contract manufacturers
  • quality teams managing glycerin and other high-risk drug components

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk